Price
No data yet.
Social Signal Score
Analyst Ratings
41 analystsRevenue
$989.71M+253.60%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Alexander Hardy
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 3,221
- Beta
- 0.24
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 1.92
Financials
Revenue
$989.71M+253.6%Net Income
$44.76MEBITDA
$222.32MFree Cash Flow
$139.29MEPS (diluted)
$0.23Shares Outstanding (diluted)
194.15M+15.8%Operating Expenses
$602.49MCash & Debt
$874.00MReturn of Capital
$28.18MRevenue by Segment (annual)
$3.22BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $3.22B | $348.90M | $1.82 |
| 2024 | $2.85B | $426.86M | $2.25 |
| 2023 | $2.42B | $167.65M | $0.89 |
| 2022 | $2.10B | $141.56M | $0.76 |
| 2021 | $1.85B | $-64.08M | $-0.35 |
| 2020 | $1.86B | $854.03M | $4.75 |
| 2019 | $1.70B | $-23.85M | $-0.13 |
| 2018 | $1.49B | $-77.21M | $-0.44 |
| 2017 | $1.31B | $-117.04M | $-0.67 |
| 2016 | $1.12B | $-630.21M | $-3.80 |
| 2015 | $889.89M | $-171.80M | $-1.07 |
| 2014 | $749.28M | $-133.97M | $-0.92 |
| 2013 | $548.49M | $-176.35M | $-1.28 |
| 2012 | $500.72M | $-114.35M | $-0.95 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $2.67
- Implied price
- $88.21
- Return from $60.00
- 8.0% a year
To earn 15.0% a year on these assumptions you'd need to buy at $43.86 — -26.9% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 23 | 28 | 33 | 38 | 43 |
|---|---|---|---|---|---|
| -2.0% | -8.8% | -5.2% | -2.0% | 0.8% | 3.3% |
| 3.0% | -4.2% | -0.3% | 3.0% | 6.0% | 8.6% |
| 8.0% | 0.5% | 4.5% | 8.0% | 11.1% | 13.9% |
| 13.0% | 5.1% | 9.4% | 13.0% | 16.2% | 19.2% |
| 18.0% | 9.8% | 14.2% | 18.0% | 21.4% | 24.4% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (30)
- Newsprnewswire.com·17h ago·Neutral
BioMarin Appoints Cara Bauer as Chief People Officer Ms. Bauer Brings More Than 25 Years of Experience in Human Resources, Across Biotechnology and Technology Industries Appointment Effective Oct. 5, 2026 SAN RAFAEL, Calif., Oct. 5, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that Cara Bauer, Ph.D.
View source ↗ - Newscnbc.com·3d ago·Neutral
BioMarin reports five-year Pompe disease data showing durable motor function A BioMarin combination therapy helped adults with late-onset Pompe disease maintain walking distance over five years of continuous therapy. Respiratory function remained relatively stable, with no new safety signals identified.
View source ↗ - Newsprnewswire.com·3d ago·Positive
…durable efficacy and safety of POMBILITI + OPFOLDA in late-onset Pompe disease SAN RAFAEL, Calif., Oct. 2, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data evaluating the efficacy and safety of POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) in late-onset Pompe disease (LOPD) were presented at the 31st Annual Congress of the World Muscle Society (WMS), in Hiroshima, Japan.
View source ↗ - Newsseekingalpha.com·14d ago·Neutral
BioMarin: Why I See Significant Upside Into 2027 Q4 2026/ 2027 will be rich in catalysts for BioMarin Pharmaceutical Inc. From the presentation of 12 mg/kg BMN 351 Phase 1/2 data in Duchenne muscular dystrophy by year-end 2026 to a potential H1 2027 approval of Voxzogo for hypochondroplasia. BioMarin raised its full-year 2026 revenue guidance from $3.83 billion-$3.93 billion to $3.88 billion-$3.93 billion.
View source ↗ - Newsmarketbeat.com·17d ago·Negative
BioMarin Targets Amicus Synergies as VOXZOGO Nears $1B Milestone BioMarin Pharmaceutical NASDAQ: BMRN said it is progressing with the integration of Amicus Therapeutics while pursuing additional business-development opportunities, as executives outlined growth plans for newly acquired rare-disease products, VOXZOGO and several pipeline programs at Morgan Stanley's Global Healthcare Conference.
View source ↗ - Newszacks.com·19d ago·Negative
BioMarin Stops Voxzogo Development for Noonan Syndrome BMRN ends Voxzogo development for Noonan syndrome as the drug faces new competition and pursues other growth opportunities.
View source ↗ - Newsseekingalpha.com·21d ago·Positive
BioMarin Pharmaceutical Inc. (BMRN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript BioMarin Pharmaceutical Inc. (BMRN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsprnewswire.com·22d ago·Neutral
BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors SAN RAFAEL, Calif., Sept. 14, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the company has appointed Robert Plenge, M.D.
View source ↗ - News (RSS)yahoo·23d ago·Neutral
BioMarin Shares Jump 5% After Global Patent Settlement With Ascendis
View source ↗ - News (Marketaux)insidermonkey.com·23d ago·Positive
BioMarin Shares Jump 5% After Global Patent Settlement With Ascendis BioMarin Pharmaceutical</em[+262 characters]
View source ↗ - News (Marketaux)gurufocus.com·25d ago·Neutral
BioMarin Pharmaceutical Inc. at Citi Biopharma Back to School Summit Transcript Refinitiv StreetEvents Event Transcript [+95 characters]
View source ↗ - Newsseekingalpha.com·25d ago·Positive
BioMarin Pharmaceutical Inc. (BMRN) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript BioMarin Pharmaceutical Inc. (BMRN) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
View source ↗ - Newsseekingalpha.com·25d ago·Positive
BioMarin Pharmaceutical Inc. (BMRN) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript BioMarin Pharmaceutical Inc. (BMRN) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
View source ↗ - News (RSS)seekingalpha·26d ago·Positive
BioMarin Pharmaceutical Inc. (BMRN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·26d ago·Positive
BioMarin Pharmaceutical Inc. (BMRN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript BioMarin Pharmaceutical Inc. (BMRN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newsprnewswire.com·27d ago·Negative
…t expanding treatment with VOXZOGO to include children with hypochondroplasia SAN RAFAEL, Calif., Sept. 9, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data from the Phase 3 CANOPY-HCH-3 study evaluating VOXZOGO® (vosoritide) in children with hypochondroplasia were published in New England Journal of Medicine (NEJM) Evidence and presented at the European Society for Paediatric Endocrinology (ESPE) 2026 Annual Meeting.
View source ↗ - News (RSS)yahoo·31d ago·Negative
BioMarin (BMRN) Secured 20% U.S. Royalties on Yuviwel. Is Monetizing a Rival Better than Blocking It?
View source ↗ - Newszacks.com·32d ago·Negative
How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset BMRN turns a competitive threat into a royalty stream as Ascendis pays royalties on Yuviwel sales, reshaping the economics of competition.
View source ↗ - Newsprnewswire.com·35d ago·Neutral
BioMarin Announces Close of the Alesta Therapeutics Acquisition Acquisition adds ALE1, a potential first oral therapy for hypophosphatasia to clinical pipeline SAN RAFAEL, Calif., Sept. 1, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) said today that it completed the previously announced agreement to acquire Alesta Therapeutics.
View source ↗ - News (RSS)zerohedge·35d ago·Neutral
…xception of NVDA which rises 0.6% after Friday's slide (Apple -0.3%, Meta -0.1%, Amazon -0.4%, Alphabet -0.5%, Tesla -0.6%, Microsoft -0.6%) BioMarin Pharmaceutical (BMRN) rises 4% after the company said it had entered into binding terms with Ascendis Pharma, resolving the patent and ancillary disputes concerning Ascendis’s Yuviwel. Energy stocks (CVX +2%, XOM +2%) rise with oil as tensions spiked in the Middle East, with the US and Iran exchanging strikes for the first time in about a month and…
View source ↗ - News (RSS)investing·35d ago·Neutral
BioMarin stock jumps after Ascendis patent settlement deal
View source ↗ - Newsgurufocus.com·36d ago·Neutral
BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and
View source ↗ - News (RSS)yahoo·47d ago·Neutral
BioMarin Pharmaceutical (BMRN)’s Alesta Deal Adds New Growth Potential in Rare Diseases
View source ↗ - Newscnbc.com·47d ago·Negative
BioMarin to acquire Alesta Therapeutics for $275 million for potential rare bone disease treatment BioMarin will acquire Alesta Therapeutics for $275 million upfront, and up to an additional $215 million based on milestones. Alesta Therapeutic's lead drug is a potential treatment for hypophosphatasia (HPP).
View source ↗ - News (RSS)investing·48d ago·Neutral
Why is BioMarin Pharmaceutical stock surging today?
View source ↗ - Newszacks.com·53d ago·Positive
5 Undervalued Price-to-Book Stocks Worth Buying in August BioMarin, Invesco, Centene, HPE and Gibraltar Industries stand out as undervalued stocks with low price-to-book ratios.
View source ↗ - Newszacks.com·54d ago·Positive
BMRN vs. ILMN: Which Stock Is the Better Value Option? Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either BioMarin Pharmaceutical (BMRN) or Illumina (ILMN). But which of these two companies is the best option for those looking for undervalued stocks?
View source ↗ - Newsseekingalpha.com·54d ago·Positive
BioMarin Pharmaceutical Inc. (BMRN) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript BioMarin Pharmaceutical Inc. (BMRN) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
View source ↗ - Newsmarketbeat.com·54d ago·Neutral
BioMarin Targets Faster Deleveraging as Amicus Deal Expands Rare-Disease Growth BioMarin Pharmaceutical NASDAQ: BMRN outlined its growth strategy, integration plans for Amicus Therapeutics and pipeline priorities during a Canaccord discussion with Chief Financial Officer Brian Mueller.
View source ↗ - Newsprnewswire.com·57d ago·Neutral
BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston SAN RAFAEL, Calif., Aug. 10, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced management will present at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston.
View source ↗
Earnings
Mon, Oct 26(in 3 weeks)
Consensus estimate $1.34 per share
Typical surprise +18.5% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$1.20 vs $0.95beat
- Mon, May 4$0.76 vs $0.78miss
- Mon, Feb 23$-0.24 vs $0.17miss
- Mon, Oct 27$-0.16 vs $-0.15miss
- Mon, Aug 4$1.23 vs $0.86beat
- Thu, May 1$0.97 vs $0.71beat
Estimates and results for BMRN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BMRN officers and directors.
- Bought
- —
- Sold
- $4.5m
0 trades
8 trades
- Davis George Ericsold
- Friberg Gregory Rsold
- Guyer Charles Gregsold
- Friberg Gregory Rsold
- Davis George Ericsold
- Burkhart Erinsold
- Hubbard Cristinsold
- Burkhart Erinsold
92 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Daniel Goldmanhouse · NY10 · disclosed Apr 17, 2023 (42d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Apr 7, 2023 (24d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jan 3, 2023 (28d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jun 10, 2022 (31d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Nov 15, 2021 (28d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Jan 11, 2021 (12d later)Buy$15,001 - $50,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Nov 5, 2020 (20d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Oct 13, 2020 (28d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jan 6, 2020 (21d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jan 6, 2020 (26d later)Buy$1,001 - $15,000
- Alan Lowenthalhouse · CA47 · disclosed Sep 1, 2019 (17d later)Sell$1,001 - $15,000
- Alan Lowenthalhouse · CA47 · disclosed Sep 1, 2019 (18d later)Sell$1,001 - $15,000
- Alan Lowenthalhouse · CA47 · disclosed Sep 1, 2019 (17d later)Sell$50,001 - $100,000
- Alan Lowenthalhouse · CA47 · disclosed Sep 1, 2019 (18d later)Sell$15,001 - $50,000
- Van Taylorhouse · TX03 · disclosed Apr 15, 2019 (21d later)Sell$1,001 - $15,000
- Alan Lowenthalhouse · CA47 · disclosed Jun 10, 2018 (12d later)Buy$50,001 - $100,000
- Alan Lowenthalhouse · CA47 · disclosed May 3, 2018 (6d later)Buy$1,001 - $15,000
- Alan Lowenthalhouse · CA47 · disclosed May 3, 2018 (7d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.